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Background/aim: We aimed to investigate the prevalence of anti-RNA polymerase (RNAP) III and other autoantibodies in a group of
Turkish patients with systemic sclerosis (SSc) and their relation with clinical features.
Materials and methods: The prevalence of anti-RNAP III and other autoantibodies was analyzed in 93 patients with SSc and control
groups including 86 patients with systemic lupus erythematosus (SLE) and 65 healthy subjects, respectively. Their relationship with
diseases findings was assessed in a cross-sectional manner.
Results: Prevalences of anti-RNAP III were 2/93 (2.2%) in SSc, 1/86 (1.2%) in SLE, and 1/65 (1.5%) in the healthy group and there was no
difference among groups (P > 0.999). Anti-Sm was significantly more common in SLE patients (P < 0.001), whereas antitopoisomerase I
and anticentromere protein B were significantly more common in SSc patients (P < 0.001). There was a significant association between
antitopoisomerase I positivity and interstitial lung disease (P < 0.001), and interestingly there was also a significant association between
anti-SS-A 52 positivity and the presence of digital ulcers in patients with SSc.
Conclusion: Our data show that anti-RNAP III in SSc patients was low in frequency in a Turkish population.
Key words: Systemic sclerosis, anti-RNA polymerase III, ANA staining pattern, interstitial lung disease, digital ulcer

1. Introduction
Systemic sclerosis (SSc) is a chronic connective tissue
disease characterized by vascular damage, inflammation
resulting in fibrosis in the skin and internal organs,
and the presence of autoantibodies (1,2). SSc is mainly
classified into diffuse and limited cutaneous forms (3).
The correlation between autoantibodies and clinical
findings in SSc has been well established (4). Antinuclear
antibodies (ANAs) are present in 80%–95% of patients
with SSc (2,5). Autoantibodies such as antitopoisomerase
I antibody (ATA), anticentromere antibody (ACA), and
anti-RNA polymerase III antibody (anti-RNAP III) are
helpful for diagnosis and classification of SSc (5–9). ATA
is classically associated with the diffuse form (dcSSc) and
ACA is typically associated with the limited form (lcSSc).
ATA is also associated with pulmonary fibrosis and renal
crisis. Anti-RNAP III is reported to be associated with
dcSSc, renal crisis, and worse prognosis (10).
In this study, we aimed to investigate the prevalence
of anti-RNAP III and other autoantibodies in a group of
patients with SSc and their relation with clinical features.
* Correspondence: enesyayla@hotmail.com
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This is also the first study investigating the prevalence of
anti-RNAP III and its relation with clinical features in SSc
patients in a Turkish population.
2. Materials and methods
SSc patients followed in the Department of Rheumatology
of Ankara University Medical School referring between
October 2014 and June 2015 were included in the study.
Inclusion criteria for the patient group were diagnosis of
SSc according to the classification criteria defined by the
American College of Rheumatology (11) and being over
18 years of age. Patients were classified as having diffuse or
limited cutaneous SSc according to LeRoy’s classification
(3). Clinical data including sex, age, age at diagnosis,
duration of disease, vascular symptoms, and visceral organ
involvements were recorded. In patients with SSc, age at
the first symptom except for Raynaud’s phenomenon was
accepted as the disease onset age. Presence of Raynaud’s
phenomenon, digital ulcers, arthritis, and extent of
cutaneous sclerosis was based on history and physical
examination. Pulmonary arterial pressure (PAP) was
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detected by echocardiography and elevated systolic PAP
was defined as ≥40 mmHg. Lung involvement was defined
as typical bilateral subpleural fine reticular to advanced
fibrotic changes on high-resolution computed tomography
with or without symptoms or functional test abnormality,
gastrointestinal involvement as dysphagia and/or motility
disorder without alternative etiology, and renal crisis as
acute deterioration in kidney function with hypertension
plus compatible renal biopsy findings. As controls, we
studied the sera of 65 healthy blood donors and 86
patients with systemic lupus erythematosus (SLE). Written
informed consent was obtained from each patient and
control. The study was in compliance with the principles
outlined in the declaration of Helsinki and was approved
by the local ethics committee.
For analysis of autoantibodies, ANA was detected
by indirect immunofluorescence with Hep-2 cells at a
screening dilution of 1:100. Serum anti-RNAP III was
measured using a commercial ELISA kit (Quanta Lite
RNA Pol III, Inova Diagnostics, San Francisco, CA, USA).
Presence of autoantibodies (ATA, anticentromere protein
B [anti-CENP B], anti-PM/Scl, anti-Sm, anti-SS-A 52, antiSS-A 60, and anti-SS-B) was assessed using a commercial
test (IMTEC ANA Line Immune Assays Maxx, Human
Diagnostics, Wiesbaden, Germany).
All calculations were performed with IBM SPSS for
Windows version 21 software. The data were analyzed
using the chi-square test for comparison between groups.
Odds ratios (ORs) with 95% confidence intervals were
calculated where appropriate. P < 0.05 was considered
statistically significant.
3. Results
Clinical, laboratory, and demographic data are presented
in Table 1. Prevalences of anti-RNAP III positivity were
2/93 (2.2%) in SSc, 1/86 (1.2%) in SLE, and 1/65 (1.5%) in
the healthy control group (P > 0.999).
Serum samples of 83 (89%) SSc patients and all SLE
patients were available for analysis of presence of ANA.

The ANA staining pattern was studied for 80 (86%) SS
patients and all SLE patients. Autoantibody specificities
were studied for 82 (88%) SSc patients and all SLE patients.
ANA was not evaluated in the healthy control group. SSc
and SLE groups were compared in terms of ANA staining
pattern and autoantibody specificities. The data are
represented in Table 2. Homogeneous (OR = 6.14 [2.21–
17] P < 0.001) and cytoplasmic (OR = 3.61 [1.57–8.27], P =
0.002) staining patterns were detected significantly in favor
of SLE and centromeric staining property was significantly
in favor of SSc (OR = 0.02 [0.006–0.12], P < 0.001). AntiSm was significantly more common in SLE patients (16.3
[3.73–71.8], P < 0.001). ATA (OR = 0.32 [0.004–0.24], P <
0.001) and anti-CENP B were significantly more common
in SSc patients (OR = 0.04 [0.009–0.18], P < 0.001).
Fourteen (15.1%) SSc patients had dcSSc and 79
(84.9%) had lcSSc. Rates of interstitial lung disease (ILD)
were 92.9% and 36.7% in the dcSSc and lcSSc groups,
respectively (OR = 22.41 [2.78–180.2], P < 0.001). Data
regarding clinical features of dcSSc and lcSSc groups are
represented in Table 3.
dcSSc and lcSSc patients were compared in terms of
ANA positivity, ANA staining patterns, and autoantibody
specificities (Table 4). Centromeric staining property was
significantly in favor of lcSSc (OR = 0.16 [0.03–0.8], P =
0.017) whereas speckled and nucleolar staining properties
were significantly in favor of dcSSc (OR = 5.6 [1.4–
22.3], P = 0.008 and OR = 8.51 [2.28–31.78], P = 0.001,
respectively). ATA was significantly more common in
dcSSc patients (OR = 17.57 [4.14–74.34], P < 0.001) and
anti-CENP B in lcSSc patients (P < 0.001).
The relationships between clinical features and
specific autoantibodies (antitopoisomerase I, anti-CENP
B, SS-A 60/52, SS-B) in SSc patients were evaluated. The
relationship between ATA positivity and the presence of
ILD was significant (OR = 6.09 [1.96–18.95], P = 0.001).
Patients with positive anti-SS-A 52 had higher digital ulcer
rates (OR = 4.21 [1.22–14.49], P = 0.017).

Table 1. Clinical, laboratory, and demographic data of SSc, SLE, and healthy control groups.
SSc
n = 93

SLE
n = 86

Healthy control
n = 65

Age
(mean ± SD, years)

50.4 ± 13.4

46.5 ± 12

48 ± 11.5

P = 0.121

Sex
(female / male) (%)

83 / 10
(89.2 / 10.8)

80 / 6
(93 / 7)

58 / 7
(89.2 / 10.8)

P = 0.627

Anti-RNAP III
(n, %)

2 (2.2)

1 (1.2)

1 (1.5)

P > 0.999

SSc = Systemic sclerosis; SLE = systemic lupus erythematosus; n = number; SD = standard deviation; anti-RNAP III = anti-RNA
polymerase III.
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Table 2. ANA staining patterns and autoantibody specificities in SSc and SLE groups.*
SSc

SLE

OR (95% CI)

77 (92.8)

81 (94.2)

1.26 (0.37–4.3)

P = 0.709

Homogeneous

5 (6.2)

25 (29.1)

6.14 (2.21–17)

P < 0.001

Speckled

35 (43.8)

71 (82.6)

6.08 (2.98–12.3)

P = 0.05

Cytoplasmic

9 (11.2)

27 (31.4)

3.61 (1.57–8.27)

P = 0.002

Granular

1 (1.2)

2 (2.3)

1.88 (0.16–21.1)

P > 0.999

Nucleolar

23 (28.8)

14 (16.3)

0.48 (0.22–1.02)

P = 0.06

Centromeric

37 (46.2)

2 (2.3)

0.02 (0.006–0.12)

P < 0.001

Anti-Sm

2 (2.4)

25 (29.1)

16.3 (3.73–71.8)

P < 0.001

ATA

22 (26.8)

1 (1.2)

0.32 (0.004–0.24)

P < 0.001

Anti-histone

0

9 (10.5)

N/A

P = 0.003

Anti-CENP B

30 (36.6)

2 (2.3)

0.04 (0.009–0.18)

P < 0.001

Anti-PM/SCL

1 (1.2)

0

N/A

P = 0.304

ANA positivity
ANA staining pattern

Autoantibody specificities

ANA = Antinuclear antibody; SSc = systemic sclerosis; SLE = systemic lupus erythematosus; ATA = antitopoisomerase I antibody; OR
= odds ratio; CI = confidence interval; N/A = not applicable.
*Serum samples of 83 (89%) SSc patients and all SLE patients were available for analysis of ANA. The ANA staining pattern was studied
in 80 (86%) SSc patients and in all SLE patients. Autoantibody specificities were studied in 82 (88%) SSc patients and in all SLE patients.
All data are represented as number (percentages).
Table 3. Clinical features of SSc patients.
dcSSc
n = 14 (15.1%)

lcSSc
n = 79 (84.9%)

Sex, female †

11 (78.6)

72 (91.1)

P = 0.171

Age ± SD, years

52.9 ± 13.2

49.9 ± 13.5

P = 0.451

Disease onset ± SD, years

45.1 ± 15.8

44.2 ± 13.4

P = 0.269

Disease duration ± SD, years

8 ± 6.46

6.35 ± 7.3

P = 0.153

Raynaud’s phenomenon †

11 (78.6)

75 (94.9)

0.19 (0.03–0.99)

P = 0.067

Digital ulcer †

7 (50)

37 (73.4)

2.76 (0.94–1.49)

P = 0.113

Digital amputation †

1 (7.1)

6 (7.6)

0.93 (0.10–8.42)

P > 0.999

Gastrointestinal involvement †

2 (14.3)

9 (11.4)

1.29 (0.24–6.75)

P = 0.757

Interstitial lung disease †

13 (92.9)

29 (36.7)

22.41(2.78–180)

P < 0.001

Elevated PAP †‡

2 (20)

11 (19.3)

1.04 (0.19–5.62)

P > 0.999

OR (95% CI)

SSc = Systemic sclerosis; dcSSc = diffuse cutaneous SSc; lcSSc = limited cutaneous SSc; n = number; PAP = pulmonary arterial pressure,
years = years; SD = standard deviation; OR = odds ratio; CI = confidence interval.
† Data are represented as numbers (percentages).
‡Four (29%) dcSSc patients and 22 (28%) lcSSc patients lacked echocardiographic PAP measurements.
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Table 4. ANA staining pattern and autoantibody specificities in dcSSc and lcSSc.*
dcSSc
(n, %)

lcSSc
(n, %)

OR (95% CI)

13 (100)

64 (91.4)

N/A

P = 0.583

Homogeneous

1 (7.7)

4 (6)

1.31 (0.13–12.78)

P > 0.999

Speckled

10 (76.9)

25 (37.3)

5.6 (1.4–22.3)

P = 0.008

Cytoplasmic

1 (7.7)

8 (11.9)

0.61 (0.07–5.38)

P > 0.999

Granular

0 (0)

1 (1.5)

N/A

P > 0.999

Nucleolar

9 (69.2)

14 (20.9)

8.51 (2.28–31.78)

P = 0.001

Centromeric

2 (15.4)

35 (52.2)

0.16 (0.03–0.8)

P = 0.017

Anti-CENP B

0 (0)

30 (43.5)

N/A

P = 0.003

ATA

11 (84.6)

11 (15.9)

17.57 (4.14–74.34)

P = 0.001

Anti-RNAP III

1 (7.1)

1 (1.3)

6 (0.35–102.01)

P = 0.28

ANA positivity
ANA staining pattern

Autoantibody specificities

n = Number; ANA = antinuclear antibody; dcSSc = diffuse cutaneous systemic sclerosis; lcSSc = limited cutaneous systemic sclerosis;
CENP B = centromere protein B; ATA = antitopoisomerase I antibody; RNAP III = RNA polymerase III; N/A = not applicable.
*Serum samples of 83 (89%) SSc patients were available for analysis of ANA. ANA staining pattern was studied in 80 (86%) and
autoantibody specificities were studied in 82 (88%) SSc patients.
Table 5. Frequency of SSc-specific autoantibodies in different racial groups (24–27).
Turkish

Mexican
(24)

Caucasian
(25)

Japanese
(26,27)

African
American (25,27)

Anti-CENP or ACA (%)

36.6

29

32

16

4–11

ATA (%)

26.8

28

13

25–28

24–26

Anti-PM/SCL(%)

1.2

9

2–4

0

0–3

Anti-RNAP III (%)

2.2

1.4

8

5

13–14

SSc = Systemic sclerosis; anti-CENP = anticentromeric protein; ACA = anticentromere antibody; ATA = antitopoisomerase I antibody;
anti-PM/SCL = antipolymyositis/scleroderma; anti-RNAP III = anti-RNA polymerase III.

4. Discussion
Prevalence of anti-RNAP III in SSc patients varies in
previously published studies. In a cohort study from
Pittsburgh, USA, prevalence was 25% (12). In studies
conducted in Europe it is found that prevalence decreases
from north to south, being 22% in Sweden, 12% in
England, 8% in Italy, and 5% in Poland. In a multicenter
study performed in France, prevalence of anti-RNAP
III was found to be 9.4%. Studies conducted in Asian
countries observed a further decrease in the prevalence, at

6% in Japan and 3.4% in South Korea (6,12–17). We found
only two anti-RNAP III-positive cases among 93 SSc
patients (2.2%). There are several reasons for the variation
in prevalence. First, anti-RNAP III prevalence varies
depending on the method used. In a study conducted in
France, different results were obtained in evaluations made
using two different ELISA kits (13,18,19). Second, patient
selection also affects the prevalence of anti-RNAP III. For
example, in a study conducted by Parker et al., SSc patients
were selected according to their ANA staining properties
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and a high prevalence (15.4%) was reported (20). Another
study was conducted among patients diagnosed with
dcSSc and the prevalence was detected to be 67% (10).
Determination of different prevalences among the abovementioned studies, conducted in many different countries,
raises concerns about race and ethnicity (19). In our study,
prevalence of anti-RNAP III was 2.2% in SSc cases, 1.2%
in SLE cases, and 1.5% in healthy subjects and there was
no significant difference between groups. The reason for
this may be the relatively low number of patients, the
cross-sectional manner of the study, and patient selection.
Prospective cohort studies will be more informative for
true incidences and disease phenotype–autoantibody
associations in patients with SSc.
Previous studies have shown the associations of antiRNAP III with higher modified Rodnan skin scores
(mRSS), renal crisis, tendon friction rubs, and dcSSc (5,6–
9). None of our SSc patients had a history of renal crisis
and as a limitation we did not evaluate tendon friction
rubs or mRSS. We had two anti-RNAP III-positive SSc
patients, one with dcSSc and the other with lcSSc, and
further statistical analysis was not possible.
Vascular phenomena (Raynaud’s and digital ulcers)
frequency and high pulmonary arterial pressure were
found to be significantly less common in ANA-negative SSc
patients than ANA-positive SSc patients (21). In the same
study, there was no significant relationship between ANA
positivity and ILD and there was a significant relationship

between negative ANA and gastrointestinal involvement.
In our study, we detected no significant relationship
between ANA positivity with abnormal capillaroscopy,
Raynaud’s phenomenon, digital ulcers, gastrointestinal
involvement, and ILD. Despite the known association
between high ACA titers and pulmonary hypertension
(22), we found no relationship between positive antiCENP B and high systolic PAP.
Association between positive anti-SS-A 52 and the
presence of digital ulcers was not reported before in
patients with SSc, although anti-SS-A 52 was previously
reported to be associated with pulmonary fibrosis in
patients with mixed connective tissue disorder (23). This
issue requires a more detailed research.
Previous studies investigated the frequency of SScspecific autoantibodies in different ethnic groups (24–27).
These studies have demonstrated that there are differences
in the distribution of autoantibodies. We compared the
results of these studies with our own data in Table 5.
In conclusion, the prevalence of anti-RNAP III differs
in different populations and is relatively low in Turkish
patients with SSc.
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